Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047801 · ClinicalTrials.gov registry record · Phase 1
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Telik.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00047801 is a Phase 1 study that has completed, run by Telik. The registered enrollment target is 28 participants.
The verdict
NCT00047801, a Phase 1 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Interventions
- DRUG TLK286 in combination with docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-10 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047801
The ClinicalTrials.gov registry entry for NCT00047801 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TLK286 in combination with docetaxel is the first listed.
NCT00047801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047801 about?
NCT00047801 is a clinical study titled "Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer". The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
What is the current status of trial NCT00047801?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2002-10. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00047801?
The interventions under investigation include: TLK286 in combination with docetaxel (DRUG).
Who is sponsoring clinical trial NCT00047801?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.